Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 27 studies | 35% ± 15% | |
classical monocyte | 23 studies | 37% ± 13% | |
monocyte | 15 studies | 31% ± 12% | |
conventional dendritic cell | 13 studies | 28% ± 15% | |
dendritic cell | 10 studies | 30% ± 11% | |
myeloid cell | 9 studies | 31% ± 6% | |
non-classical monocyte | 9 studies | 21% ± 6% | |
endothelial cell | 6 studies | 27% ± 9% | |
microglial cell | 6 studies | 42% ± 21% | |
endothelial cell of lymphatic vessel | 6 studies | 33% ± 11% | |
neutrophil | 5 studies | 32% ± 14% | |
oligodendrocyte | 5 studies | 37% ± 21% | |
mononuclear phagocyte | 5 studies | 32% ± 13% | |
intermediate monocyte | 4 studies | 35% ± 11% | |
astrocyte | 4 studies | 28% ± 17% | |
fibroblast | 4 studies | 26% ± 4% | |
leukocyte | 3 studies | 16% ± 0% | |
GABAergic neuron | 3 studies | 20% ± 3% | |
epithelial cell | 3 studies | 18% ± 2% | |
tissue-resident macrophage | 3 studies | 35% ± 12% | |
T cell | 3 studies | 19% ± 2% | |
oligodendrocyte precursor cell | 3 studies | 31% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 278.09 | 577 / 578 | 7% | 0.11 | 78 / 1155 |
breast | 97% | 106.47 | 445 / 459 | 8% | 0.13 | 90 / 1118 |
kidney | 92% | 72.60 | 82 / 89 | 11% | 0.21 | 99 / 901 |
thymus | 99% | 160.32 | 648 / 653 | 3% | 0.06 | 20 / 605 |
brain | 89% | 73.87 | 2355 / 2642 | 12% | 0.20 | 86 / 705 |
intestine | 98% | 104.07 | 950 / 966 | 2% | 0.03 | 9 / 527 |
spleen | 100% | 819.50 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 153.34 | 1196 / 1204 | 0% | 0 | 0 / 0 |
bladder | 95% | 85.90 | 20 / 21 | 3% | 0.10 | 17 / 504 |
ovary | 97% | 97.57 | 175 / 180 | 1% | 0.02 | 5 / 430 |
prostate | 98% | 104.32 | 240 / 245 | 0% | 0.01 | 2 / 502 |
adrenal gland | 97% | 96.54 | 251 / 258 | 0% | 0 | 0 / 230 |
uterus | 96% | 101.39 | 164 / 170 | 1% | 0.01 | 3 / 459 |
peripheral blood | 96% | 1663.20 | 894 / 929 | 0% | 0 | 0 / 0 |
stomach | 88% | 61.55 | 316 / 359 | 6% | 0.11 | 18 / 286 |
blood vessel | 94% | 86.18 | 1249 / 1335 | 0% | 0 | 0 / 0 |
esophagus | 88% | 61.99 | 1278 / 1445 | 1% | 0.01 | 1 / 183 |
liver | 88% | 52.83 | 198 / 226 | 0% | 0.00 | 1 / 406 |
pancreas | 82% | 46.57 | 269 / 328 | 2% | 0.02 | 3 / 178 |
skin | 80% | 54.25 | 1439 / 1809 | 3% | 0.03 | 12 / 472 |
heart | 81% | 49.98 | 697 / 861 | 0% | 0 | 0 / 0 |
muscle | 28% | 10.52 | 223 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 28% | 0.47 | 8 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0043154 | Biological process | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0002221 | Biological process | pattern recognition receptor signaling pathway |
GO_0006954 | Biological process | inflammatory response |
GO_0016045 | Biological process | detection of bacterium |
GO_0046456 | Biological process | icosanoid biosynthetic process |
GO_0045087 | Biological process | innate immune response |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0070269 | Biological process | pyroptotic inflammatory response |
GO_0032731 | Biological process | positive regulation of interleukin-1 beta production |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0042742 | Biological process | defense response to bacterium |
GO_0006915 | Biological process | apoptotic process |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0043524 | Biological process | negative regulation of neuron apoptotic process |
GO_0010804 | Biological process | negative regulation of tumor necrosis factor-mediated signaling pathway |
GO_0007399 | Biological process | nervous system development |
GO_0072557 | Cellular component | IPAF inflammasome complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0061702 | Cellular component | canonical inflammasome complex |
GO_0016323 | Cellular component | basolateral plasma membrane |
GO_0004869 | Molecular function | cysteine-type endopeptidase inhibitor activity |
GO_0043027 | Molecular function | cysteine-type endopeptidase inhibitor activity involved in apoptotic process |
GO_0120283 | Molecular function | protein serine/threonine kinase binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
GO_0016887 | Molecular function | ATP hydrolysis activity |
Gene name | NAIP |
Protein name | Baculoviral IAP repeat-containing protein 1 (NAIP protein) Baculoviral IAP repeat-containing protein 1 (Neuronal apoptosis inhibitory protein) Baculoviral IAP repeat-containing protein 1 (NLR family apoptosis inhibitory protein) Baculoviral IAP repeat-containing protein 1 NLR family apoptosis inhibitory protein |
Synonyms | BIRC1 |
Description | FUNCTION: Anti-apoptotic protein which acts by inhibiting the activities of CASP3, CASP7 and CASP9. Can inhibit the autocleavage of pro-CASP9 and cleavage of pro-CASP3 by CASP9. Capable of inhibiting CASP9 autoproteolysis at 'Asp-315' and decreasing the rate of auto proteolysis at 'Asp-330'. Acts as a mediator of neuronal survival in pathological conditions. Prevents motor-neuron apoptosis induced by a variety of signals. Possible role in the prevention of spinal muscular atrophy that seems to be caused by inappropriate persistence of motor-neuron apoptosis: mutated or deleted forms of NAIP have been found in individuals with severe spinal muscular atrophy.; FUNCTION: Acts as a sensor component of the NLRC4 inflammasome that specifically recognizes and binds needle protein CprI from pathogenic bacteria C.violaceum. Association of pathogenic bacteria proteins drives in turn drive assembly and activation of the NLRC4 inflammasome, promoting caspase-1 activation, cytokine production and macrophage pyroptosis. The NLRC4 inflammasome is activated as part of the innate immune response to a range of intracellular bacteria such as C.violaceum and L.pneumophila. |
Accessions | A0A0G2JNC7 ENST00000610590.4 ENST00000616766.2 ENST00000503719.6 [Q13075-2] ENST00000628482.2 ENST00000629198.2 Q13075 H0YAX2 A0A0G2JQE0 ENST00000619206.4 ENST00000620988.4 ENST00000615009.3 ENST00000508426.6 ENST00000616067.4 ENST00000622005.4 ENST00000612328.4 ENST00000519014.1 ENST00000194097.8 [Q13075-1] A0A0G2JS53 ENST00000523981.5 [Q13075-2] E7EQW0 B7ZLE8 ENST00000517649.6 [Q13075-1] ENST00000514857.2 E5RJA3 ENST00000625431.2 ENST00000618877.1 |